Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT.
Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT; Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT.
J Cardiothorac Vasc Anesth. 2020 Jul;34(7):1933-1941. doi: 10.1053/j.jvca.2019.09.022. Epub 2019 Sep 18.
Postoperative atrial fibrillation (POAF) after cardiac surgery remains a highly prevalent and costly condition that negatively impacts patient quality of life and survival. Numerous retrospective studies, meta-analysis, and review papers have been reported identifying POAF risk based on patients' risk factors and clinical biomarkers. In this narrative review, the authors report significant variations among selected pre- and perioperative biomarkers used to predict POAF incidence in patients without a history of atrial fibrillation (AF). POAF prediction based on B-type natriuretic peptide, N-terminal pro B-type natriuretic peptide, C-reactive protein, interleukin-6, creatinine, and plasminogen activator inhibitor-1 differs significantly among different studies, thereby limiting their clinical utility to predict POAF risk with high accuracy. Conversely, soluble vascular endothelial cells adhesion molecule-1, soluble CD40 ligand, Galectin-3, and aldosterone show promise for better POAF prediction. However, the current datasets for these selected biomarkers are not of sufficient size to validate the broad clinical application specifically for patients with no prior history of AF.
心脏手术后的心房颤动(POAF)仍然是一种高发且昂贵的疾病,会对患者的生活质量和生存率产生负面影响。许多回顾性研究、荟萃分析和综述论文已经报道了基于患者的风险因素和临床生物标志物来识别 POAF 风险。在这篇叙述性综述中,作者报告了在没有心房颤动(AF)病史的患者中,用于预测 POAF 发生率的选定术前和围手术期生物标志物之间存在显著差异。基于 B 型利钠肽、N 端脑利钠肽前体、C 反应蛋白、白细胞介素 6、肌酐和纤溶酶原激活物抑制剂 1 的 POAF 预测在不同研究中差异显著,从而限制了其以高精度预测 POAF 风险的临床实用性。相反,可溶性血管内皮细胞黏附分子 1、可溶性 CD40 配体、半乳糖凝集素-3 和醛固酮显示出更好的 POAF 预测的潜力。然而,这些选定生物标志物的当前数据集还不够大,无法针对没有 AF 既往史的患者进行广泛的临床应用验证。